US › Healthcare

Grace Therapeutics, Inc. (GRCE)

US · Healthcare · Biotechnology

$1.89-3.08%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-15.8M

EPS

$-0.91

EPS estimate

$-0.18

EPS came in at -0.91 against a street estimate of -0.18 — a miss of 405.6%.

Key statistics

Market cap

$41.9M

Forward P/E

2.2

P/B

0.93

Book value

$2.96

EPS (TTM)

$-1.17

52-week high

$5.18

52-week low

$1.79

50-day MA

$2.13

200-day MA

$2.93

Beta

0.33

Analyst view

Analysts rate Grace Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.87.

Shareholding

Insiders

18.68%

Institutions

31.51%

Largest institutional holders

Fund	Stake
HPM Partners LLC	5.22%
Eversept Partners, LP	4.75%
Bank of America Corp	3.04%
Vanguard Capital Management, LLC	2.53%
Citadel Advisors Llc	2.15%
CANTOR FITZGERALD, L. P.	1.23%
MAVEN SECURITIES Ltd	1.23%
Birchview Capital, LP	0.74%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Grace Therapeutics, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.